INSERM U1058, University of Montpellier I, Department of Dermatology, and UFR Pharmacy, Hôpital Saint-Eloi, Montpellier, France.
Eur J Dermatol. 2013 Apr 1;23(2):202-7. doi: 10.1684/ejd.2013.1933.
Solar urticaria is a rare, disabling, chronic disease. Few large series are available.
To report the epidemiological, clinical, phototesting, treatment and patient outcome data of a large series.
Data from 61 patients' files were retrospectively retrieved in a tertiary referral centre.
43 women and 18 men were included (mean age at first symptoms: 34 y). 3 patients had a medical history of chronic urticaria and 29% of atopy. Urticaria occurred before the 15(th) minute of sun-exposure in 95% of the patients and resolved spontaneously after its interruption within 1h in 76.4%. Determination of the action spectra revealed UVA sensitization in 91.8% of the patients, alone (49.2%) or with UVB (24.6%) or visible light (14.75%). 61.7% of the patients received antihistamines, 75% noted a significant improvement. 36.2% benefited from UVA phototherapy and were satisfied. 3 patients reported complete remission after 4 to 11 years.
Our study is the second largest in the literature. Main discrepancies with previous series concern the absence of associated photodermatoses and the predominance of UVA sensitization over visible light, which could be explained by suboptimal phototesting in the most ancient cases. Interpretation of our results is restricted because data were missing in 10 to 25% of the patients' files. The response to treatment was evaluated upon the dermatologist's observation, which highlights the need of validated tools to evaluate patients' disability and response to treatment.
日光性荨麻疹是一种罕见的、使人丧失能力的慢性疾病。目前仅有少数大样本系列研究。
报告一个大型系列的流行病学、临床、光试验、治疗和患者结局数据。
在一个三级转诊中心,回顾性检索了 61 份患者病历中的数据。
纳入 43 名女性和 18 名男性(首次出现症状时的平均年龄:34 岁)。3 名患者有慢性荨麻疹病史,29%的患者有特应性。95%的患者在暴露于阳光后 15 分钟内出现荨麻疹,76.4%的患者在中断暴露后 1 小时内可自发缓解。确定作用光谱显示,91.8%的患者存在 UVA 敏化,单独存在(49.2%)或与 UVB(24.6%)或可见光(14.75%)同时存在。61.7%的患者接受了抗组胺治疗,75%的患者认为有显著改善。36.2%的患者受益于 UVA 光疗并感到满意。3 名患者在 4 至 11 年后报告完全缓解。
我们的研究是文献中的第二大研究。与之前的系列研究主要存在差异,包括没有伴发性光皮病和 UVA 敏化比可见光更为常见,这可能是由于最古老病例中的光试验不够理想所致。由于在 10%至 25%的患者病历中存在数据缺失,因此对我们结果的解释受到限制。治疗反应是根据皮肤科医生的观察来评估的,这突出了需要有效的工具来评估患者的残疾和治疗反应。